I would like to highlight the answer by TK to one of the questions. The question was: How are numbers going in the Phospherous Covid testing in the US, and would we consider perhaps Australia as a testing ground? TK's answer: We will be publishing an update in the next month or so and US participant numbers have picked up recently. We are certainly considering Australian locations as well, but numbers here are low. We are looking at other countries and locations as well, but also to broaden the dataset both with patients but also longitudially which may tell about disease progression. The endgame is not just the US clinical study. We are looking at other options.
I wonder what other options there are that TK is talking about? Mapping disease progression could well be beneficial. If cough or breathing sound A leads to a worsening condition B in many of the patients, then acting on A may save patients from deteriorating with appropriate medical intervention. Just my fanciful speculation, not medical fact.
- Forums
- ASX - By Stock
- RAP
- Ann: Quarterly Results and Investor Conference Call Notification
Ann: Quarterly Results and Investor Conference Call Notification, page-32
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online